Science
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
A vaccine manufactured in plants and developed in Canada 24/02/2022 — QUEBEC CITY & LONDON — (BUSINESS WIRE) Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today […]
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
15/02/2022 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a strategic collaboration with the Moores Cancer Center […]
Agendia Study Demonstrates MammaPrint® and BluePrint® Capture Full Spectrum of Early Breast Cancer Biology, Providing Opportunity for Highly Individualized Treatment
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study […]
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally 10/01/2022 — IRVINE, Calif. & AMSTERDAM — […]
Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate
Final portion of data submitted as part of New Drug Submission for COVID rolling review COVID-19 vaccine candidate fully developed in Canada submitted for authorization 16/12/2021 — QUEBEC CITY — […]
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
16/12/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Personal, a next-generation, tumor-informed liquid […]
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint® as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age effect and lymph node status for patients with breast cancer 10/12/2021 — IRVINE, Calif. & AMSTERDAM — (BUSINESS WIRE) Agendia, […]
Medicago and GSK Announce Positive Phase 3 Efficacy and Safety Results for Adjuvanted Plant-Based COVID-19 Vaccine Candidate
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants Efficacy demonstrated against all variants seen in the study, including 75.3% efficacy […]
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per the paper, […]
LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
01/12/2021 — GUANGZHOU, China — (BUSINESS WIRE) LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today […]
DEXLEVO, International Commercialization Outcomes and the “Green Light” for IPO
16/11/2021 — SEOUL, South Korea — (BUSINESS WIRE) DEXLEVO achieved a sales of 30 billion dollars after CE certification for liquid polymer fillers for the first time in the world. […]
Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
02/11/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding […]
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
– Trial Designed to Support an Accelerated Approval Application in the U.S. – 28/09/2021 — BOTHELL, Wash. — (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced it completed patient enrollment […]
CEM Corporation & AmbioPharm Form U.S. Partnership for GMP Peptide Production
14/09/2021 — MATTHEWS, N.C. & NORTH AUGUSTA, S.C. — (BUSINESS WIRE) CEM Corporation and AmbioPharm, Inc. are excited to announce the formation of a partnership for production of GMP peptides […]
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
25/08/2021 — NOTTINGHAM, U.K. — (BUSINESS WIRE) Quotient Sciences, the drug development and manufacturing accelerator, announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, U.K. The […]
Ultivue Announces New Independent Board Members
19/08/2021 — CAMBRIDGE, Mass. — (BUSINESS WIRE) Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader […]
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
11/08/2021 — FRANKFURT, Germany — (BUSINESS WIRE) wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., […]
Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
05/08/2021 — CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers […]
Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors
29/07/2021 — WALTHAM, Mass, — (BUSINESS WIRE) Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, […]
Centessa Announces Pricing of Initial Public Offering
28/05/2021 — CAMBRIDGE, Mass. & LONDON — (BUSINESS WIRE) Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines […]
Personalis, Inc. to Present at Biomarkers Week Online 2021
17/05/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online […]
Centessa Pharmaceuticals Announces Expansion of Management Team and Board of Directors
New Appointments Bring Expertise and Proven Leadership to Support Asset-Centric R&D Model and Portfolio Advancement 17/05/2021 — CAMBRIDGE, Mass. & LONDON — (BUSINESS WIRE) Centessa Pharmaceuticals (“Centessa”) today announced key […]
Ultivue Announces $50M Financing Round
27/04/2021 — CAMBRIDGE, Mass. — (BUSINESS WIRE) Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for […]
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 #Antibody for the Treatment and Prevention of #COVID-19
Additional Capital to Fund Ongoing STAMP Pivotal Trial of ADG20 Designed to Support Emergency Use Authorization Submission Financing Follows First Quarter Appointment of Industry and Banking Veteran Jane Henderson as […]
LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
13/04/2021 — GUANGZHOU, China — (BUSINESS WIRE) LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today […]
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
Phase 1/2/3 STAMP Trial to be Conducted Globally, Including in Countries with High Rates of SARS-CoV-2 Variants Resistant to Other Monoclonal Antibody Products Potential for Early Access to Therapy by […]
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
– Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens – – First HER-2 Tyrosine Kinase Inhibitor Combination Regimen to […]
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
09/02/2021 — NOTTINGHAM, England — (BUSINESS WIRE) Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). […]
MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
Triastek Opens a New Chapter for Digital Formulation Development and Intelligent Pharmaceutical Manufacturing 09/02/2021 — NANJING, China — (BUSINESS WIRE) Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing […]
AmbioPharm Inc. Announces New Shanghai Campus Opening and European Executive Team Members
07/01/2021 — NORTH AUGUSTA, S.C. — (BUSINESS WIRE) AmbioPharm Inc., a worldwide leader in peptide API CDMO services, has recently opened its new Shanghai campus. The new campus adds nearly […]